AISLENCT07913919
Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Comparison of coronary artery 68Ga-DOTATATE maximum tissue-to-blood ratio (TBRmax) after 16 weeks of anifrolumab compared to baseline
Timeframe: Between baseline and following 16 weeks of anifrolumab therapy
Secondary (1)
Comparison of ascending aortic 68Ga-DOTATATE TBRmax after 16 weeks of anifrolumab compared to baseline
Arms and interventions
Anifrolumab armExperimental
In this single arm of the study patients with patients will undergoing PET/MRI before and after anifrolumab therapy
Diagnostic tests: 68-Gallium Dotatate
Drugs: Anifrolumab
Sites
1 site in 1 country
- Addenbrookes HospitalCambridge, Cambridgeshire, United Kingdom